GOVX Stock Cash Flow Statements

GeoVax Labs Quarterly Cash Flow Statements Chart

Quarterly

Annual

Stock-Based Compensation

Operating Cash Flow

Investing Cash Flow

Financing Cash Flow

Free Cash Flow

Capital Expenditure

GeoVax Labs Quarterly Cash Flow Statements Table

Quarterly

Annual

Unit: USD	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31

cash flows from operating activities:
net income	-5,064,042	-5,850,132	-7,592,408	-8,408,818	-5,927,620	-4,037,916	-5,383,809	-3,968,102	-2,241,699	-2,427,515	-13,743,003	-1,950,503	-1,314,033	-1,562,778	-1,336,522	-570,648	-455,204	-595,694	-590,593	-424,434	-654,148	-701,454	-634,345	-666,893	-637,043	-621,813
adjustments to reconcile net income to net cash from operating activities:
depreciation and amortization expense
stock-based compensation expense	101,640	157,736	261,458	297,947	269,513	246,039			207,178	205,151			122,031	76,790	40,463	6,000	12,000	6,000	36,756	32,348	105,172	153,224	194,299	142,512	80,364	52,549
changes in assets and liabilities:
accounts receivable
prepaid expenses and other current assets	112,385	-677,033	592,596	-8,299	57,188	-755,973	85,834	-312,052	-801,119	-138,368	-123,249	70,928	392	35,659	-106,976	27,424	27,425	27,425	27,426	-83,607	0	-30	-26,064	20,849	20,847	20,848
other assets	224,681	882,097	0	10,000	0	976,498
accounts payable and accrued expenses			-3,561,804	2,996,173				1,421,537	-133,235	-1,934,257	7,099,710	-23,372	91,773	-357,878	-114,080	87,954	-490,479	654,561	208,112	169,106	-5,401	267,465	66,706	233,611	145,697	107,105
total adjustments	3,122,994	166,402	-2,685,537	3,313,140	-109,524	275,044	-1,680,427	168,948	-1,591,879	-1,905,725	7,059,854	316,798	55,494	-58,249	-205,429	287,522	-111,669	237,074	309,833	80,506	197,700	384,093	132,804	387,166	256,858	240,240
net cash from operating activities	-1,941,048	-5,683,730	-10,277,945	-5,095,678	-6,037,144	-3,762,872	-7,064,236	-3,799,154	-3,833,578	-4,333,240	-6,683,149	-1,633,705	-1,258,539	-1,621,027	-1,541,951	-283,126	-566,873	-358,620	-280,760	-343,928	-456,448	-317,361	-501,541	-279,727	-380,185	-381,573
capex	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-154,321	0	0	0	-3,334	0	0	-4,272	0	0	0	0
free cash flows	-1,941,048	-5,683,730	-10,277,945	-5,095,678	-6,037,144	-3,762,872	-7,064,236	-3,799,154	-3,833,578	-4,333,240	-6,683,149	-1,633,705	-1,258,539	-1,621,027	-1,696,272	-283,126	-566,873	-358,620	-284,094	-343,928	-456,448	-321,633	-501,541	-279,727	-380,185	-381,573
cash flows from investing activities:
purchase of equipment			-18,949	-6,192			0	-51,875	-20,197	-62,186
net cash from investing activities			-18,949	-6,192			0	-51,875	-20,197	-62,186	0	-27,789			-154,321				-3,334	0	0	-4,272
cash flows from financing activities:
net proceeds from issuance of notes payable – related parties
net proceeds from sale of common stock and warrants							0			9,229,248	0				0
net proceeds from warrant exercise										24
net cash from financing activities							0	7,625,543	18,498,513	9,229,272	0	230,000	-25,801	12,580,013	-526	11,155,508	1,055,748	297,086	-1,924	696,876	496,874	237,917	250,000	600,000
net decrease in cash and cash equivalents	792,853	-5,683,730
cash and cash equivalents at beginning of period	0	6,452,589	0	0	0	27,612,732	0	0	0	11,423,870	0	0	0	9,883,796	0	0	0	283,341	0	0	0	259,701	0	0	0	312,727
cash and cash equivalents at end of period	792,853	768,859	-6,234,452	-5,101,870	-6,060,949	23,849,860	-7,064,236	3,774,514	14,644,738	16,257,716	-6,683,149	-1,431,494	-1,304,269	20,842,782	-1,696,798	10,869,912	488,875	221,807	-286,018	352,948	40,426	175,985	-251,541	320,273	-380,185	571,154
depreciation expense		19,576		17,319	17,318	17,319				12,269
accounts payable, accrued expenses and other liabilities		-215,974				-208,839
none
depreciation and amortization							14,071	17,675			11,715	8,935	13,354	4,517	16,673	-4,050	6,039	994	2,657	1,898	1,898	1,897	4,920	4,951	4,950	4,980
grant funds receivables
net proceeds from warrant exercises							0	7,625,543			0	230,000	0	3,174,156
net increase in cash and cash equivalents			-6,234,452	-5,101,870	-6,060,949	-3,762,872	-7,064,236	3,774,514	14,644,738	4,833,846	-6,683,149	-1,431,494	-1,304,269	10,958,986	-1,696,798	10,869,912	488,875	-61,534	-286,018			-83,716		320,273	-380,185	258,427
grant funds receivable																								-14,757
warrant issued for technology license
gain on debt extinguishment											0	0
repurchase of preferred stock											0	0
principal repayment of note payable											0	0	-24,801	-3,063		-2,988	-2,952	-2,914		-3,124	-3,126	-2,083
stock-based compensation expense for employees and directors
stock-based compensation expense for consultants
grant funds and other receivables								0	99,526	-50,520	-49,006	0	0	182,663	-41,509	46,009	333,346	-451,906	34,882	-39,239	96,031	-38,463				54,758
deposits and other assets								-1,196,778
cash flows from investing activities
net proceeds from sale of common stock													0	9,408,920
amortization of debt discount															0
warrant issued for technology license fee											0
purchase of property and equipment											0				-154,321				-3,334	0	0	-4,272
net proceeds from sale of preferred stock															0	0	0	300,000	0	700,000	500,000	240,000	0	600,000	0	590,000
net proceeds from issuance of note payable															0	0
net proceeds from bridge financing															0	0
stock-based compensation for employees and directors
stock-based compensation for consultants
principal repayment of notes payable
proceeds from issuance of notes payable
proceeds from issuance of note payable																								0	0	50,000
net cash provided in financing activities																										640,000
stock-based compensation expense, including common stock issued for services
proceeds from sale of common stock
proceeds from sale of preferred stock
accretion of preferred stock redemption value
deferred offering costs
deposits
proceeds from sale of property and equipment
net cash provided (used) by investing activities
supplemental disclosure of cash flow information interest paid
write-off of deferred offering costs
supplemental disclosure of cash flow information
interest paid
supplemental disclosure of non-cash investing and financing activities:
adjustments to reconcile net income to net cash from operating activities
changes in assets and liabilities
net cash provided (used) by financing activities
stock subscriptions receivable
in connection with the merger discussed in note 6, all of the outstanding shares of the company’s mandatory redeemable convertible preferred stock were converted into shares of common stock as of september 28, 2006.
unearned grant revenue
net proceeds from exercise of stock options
prepaid expenses
repayment of note payable

We provide you with 20 years of cash flow statements for GeoVax Labs stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as operating cash flows, cash levels, capital expenditures, profits, stock-based compensations and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of GeoVax Labs stock. Explore the full financial landscape of GeoVax Labs stock with our expertly curated income statements.

The information provided in this report about GeoVax Labs stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.